Comparative Pharmacology
Head-to-head clinical analysis: MICROGESTIN 1 20 versus PORTIA 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MICROGESTIN 1 20 versus PORTIA 21.
MICROGESTIN 1/20 vs PORTIA-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing estrogen (ethinyl estradiol) and progestin (norethindrone acetate). Inhibits gonadotropin secretion (FSH, LH) via negative feedback, preventing ovulation. Also causes cervical mucus thickening and endometrial thinning.
Oral contraceptive: inhibition of ovulation by suppressing gonadotropin release; increases viscosity of cervical mucus, reducing sperm penetration; alters endometrial receptivity.
One tablet (norethindrone acetate 1 mg / ethinyl estradiol 20 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.
One tablet (norgestimate 0.180 mg/ethinyl estradiol 0.035 mg) orally once daily for 21 days, followed by 7 days of placebo.
None Documented
None Documented
Norethindrone: 5.2-12.8 hours (mean ~8 hours); Ethinyl estradiol: 7-20 hours (mean ~13 hours); hepatic impairment prolongs.
Terminal elimination half-life: 24-30 hours; clinical context: steady-state reached after 5-7 days, allows once-daily dosing
Renal: 40% as metabolites, 20% as glucuronide and sulfate conjugates; Fecal: 35%; Biliary: <5%.
Renal (50-60% unchanged), fecal (30-40% as metabolites), minor biliary
Category C
Category C
Oral Contraceptive
Oral Contraceptive